2009) and may lack the necessary sensitivity to diagnose a separate demyelinating neuropathy in DSP patients and so the buy Etoposide diagnosis of CIDP + DM is difficult because of overlap in clinical and electrophysiological characteristics in these neuropathies. Previous nerve fiber injury due to diabetes may mask novel demyelinating changes related to immune-mediated nerve injury. Thus, it is probable that highly specific criteria for CIDP in DSP patients will have very low sensitivity. We have observed in diabetes patients, Inhibitors,research,lifescience,medical electrophysiological and clinical findings atypical for classic
DSP although insufficient for existing CIDP criteria. For example, we observed a reduction in conduction velocity in DSP out of proportion to the axonal loss, but still not in the range of defined criteria for CIDP. That raised the possibility of an unexpected degree of demyelination in the context of DSP, and we discovered that this group of patients had type 1 diabetes and suboptimal glycemic control. These findings could indicate abnormal immune mechanisms in type 1 diabetes patients producing both Inhibitors,research,lifescience,medical findings, or relate to more sensitivity
to metabolic damage of the Schwann cells in type 1 diabetes patients. Our current findings show even Inhibitors,research,lifescience,medical greater degrees of demyelination in the CIDP + DM group that are associated with a more severe neuropathy phenotype (greater weakness, more abnormal reflexes, higher TCNS scores, and more abnormal NCS), but less impaired glycemic control, supporting the diagnosis of an immune-mediated polyneuropathy rather than DSP. Limitations of the current study are as follows: Referral bias – CIDP + DM patients were accrued differently than Inhibitors,research,lifescience,medical D-DSP as they were referred based on the clinical suspicion of CIDP and may have a greater severity of disease. Also, given the difference in accrual intervals of about 10 years, bias regarding improved Inhibitors,research,lifescience,medical management may exist. NCS do not necessarily define “demyelination” – rather, they may indicate myelin or nodal dysfunction. Although the NCS patterns are similar between the two conditions, there may be structural
differences that could be discerned by other tests such as ultrasound, biopsy, or magnetic resonance imaging (MRI). Also, as clinicians might use NCS in the upper extremities to distinguish CIDP from D-DSP, exclusion of upper limb NCS may limit the observations. Misclassification is a potential error ADAMTS5 – there are no biomarkers to make a definitive diagnosis of CIDP and demyelination or conduction slowing on NCS is not a specific finding. However, the differences in clinical phenotype observed between the groups support the diagnostic classification. Also, the degree of demyelination used to define CIDP in this study are not as strict as in published criteria, but existing criteria are accepted as lacking high sensitivity and recent approaches employ more relaxed criteria (Koski et al. 2009; Brannagan 2011).